Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

BACKGROUND: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial(1) prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory non–small-cell lung cancer (NSCLC) patients into four phase II trials: erlotinib, erlotinib-bexarotene, van...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Thorac Oncol
Egile Nagusiak: Tsao, Anne S., Liu, Suyu, Lee, J. Jack, Alden, Christine M., Blumenschein, George R., Herbst, Roy, Davis, Suzanne E., Kim, Edward, Lippman, Scott, Heymach, John, Tran, Hai, Tang, XiMing, Wistuba, Ignacio, Hong, Waun Ki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118909/
https://ncbi.nlm.nih.gov/pubmed/23584298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31828d08ae
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak